Cotadutide's effects on metabolism and liver health in overweight adults with type 2 diabetes over 54 weeks

Cotadutide significantly decreased glycated hemoglobin A (HbA1c) and body weight at weeks 14 and 54 compared to placebo (all < 0.001).

• Improvements in lipid profile, liver enzyme levels, and liver fibrosis assessments were noted with cotadutide 300 μg compared to placebo.
• Weight loss achieved with cotadutide 200 μg was comparable to liraglutide 1.8 mg, while cotadutide 300 μg resulted in greater weight loss than liraglutide.
• The most common adverse events associated with cotadutide were nausea (35%) and vomiting (17%), which decreased over time.
• Cotadutide treatment is associated with enhanced glycemic control and weight reduction in individuals with overweight/obesity and type 2 diabetes.
• Preliminary analyses suggest potential benefits of cotadutide for liver health, indicating a need for further investigation in nonalcoholic steatohepatitis (NASH).

Simplified